Redsense’s application for admission to trading on Spotlight Stock Market has been approved
Spotlight has today approved Redsense Medical AB´s application for admission to trading of the Company´s shares on Spotlight Stock Market. The first day of trading will be on May 3, 2019.
Redsense’s shares are today traded on Nasdaq First North. Redsense has decided to act for a change of listing venue and Spotlight has today approved Redsense’s application for admission to trading of the Company’s shares on Spotlight Stock Market. First day of trading in the Company’s shares on Spotlight will be on May 3, 2019 and the last day of trading in Redsense’s shares on First North Stockholm is May 2, 2019. Redsense’s shares will continue to trade under the ticker name REDS with current ISIN- code SE0006965158. Shareholders in Redsense will not have to take any action with regards to the change of listing venue.
“We are happy and proud to have once again gained the confidence to act as the trading venue for Redsense's shares. It shows that we have a product and an offer that is valuable to our customers.” Peter Gönczi, CEO at Spotlight
“We had a very good cooperation and a rewarding relationship with Spotlight during the time we were listed on their marketplace. Spotlight gave us invaluable support in regulatory issues and market communication, which gives us at Redsense time to focus on what we do best, namely to conduct our business and demonstrate continued growth.” Patrik Byhmer, CEO of Redsense Medical.
For more information, please contact:
Head of Listing, Spotlight
+46 8 511 68 008
+46 70 7749303
+46 8 511 68 000
Spotlight is the marketplace where investors and growth companies meet. At Spotlight it is easier and safer for companies to be listed. We offer an overall solution that increase the visibility for our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in more than 170 growth companies from different businesses and countries, among those are Freetrailer, Bahnhof and Synthetic MR.